Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.
Also Read: AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race The company shared data from a double-blind, randomized, placebo ...
Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
AstraZeneca CEO Pascal Soriot acknowledged when the company announced the Eccogene deal in November 2023 that his company ...
Miller Value Partners portfolio manager John Spallanzani joined ‘Mornings with Maria’ to discuss the U.S. economy and stock market as oil prices fall to $78 a barrel. Sen. Shelley Moore Capito, R-W.
Shareholders in Disney will see if CEO Bob Iger still has a midas touch and in Asia, Alibaba is expected to deliver yet ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...